|Bid||3.1100 x 800|
|Ask||3.2000 x 800|
|Day's Range||3.0800 - 3.2700|
|52 Week Range||2.7000 - 11.5500|
|Beta (3Y Monthly)||5.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
The following companies are falling knives since their share prices have declined more than 59% over the past year through May 13. Wall Street issued a recommendation rating of overweight to buy for all three stocks, increasing the likelihood of them outperforming the S&P 500 index within 52 weeks. Warning! GuruFocus has detected 5 Warning Signs with CLDX.
The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experimental cancer drug glemba.
Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of $1.40. Losses, adjusted for asset impairment costs and non-recurring costs, came to $1.13 per share. The biopharmaceutical ...
HAMPTON, N.J., May 07, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex.
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Therapeutics, Inc. (CLDX) presented interim data from the Company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer Research (AACR) Annual Meeting 2019. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.CDX-1140 is a fully human agonist anti-CD40 monoclonal antibody that was specifically designed to balance good systemic exposure and safety with potent biological activity, a profile which differentiates CDX-1140 from other CD40-activating antibodies.
Celldex Therapeutics, Inc. (CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) Annual Meeting 2019. “Our research and discovery efforts have yielded multiple promising candidates that address important needs in cancer immunotherapy and complement our pipeline,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “CDX-527 joins two powerful pathways in the immune system, PD-1 blockade and CD27 costimulation.
The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange.
HAMPTON, N.J., March 07, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 6) Chiasma Inc (NASDAQ: CHMA ) Magenta Therapeutics Inc ...
In the latest trading session, Celldex Therapeutics (CLDX) closed at $5.92, marking a -1.17% move from the previous day.
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) stock tanked Monday after the company effected a 15-to-1 reverse stock split that was first announced two days ago. The reverse split pushed Celldex’s share price from about 39 cents to about $5 per share, but the market’s negative initial reaction to the decision is typical of the response to reverse splits. Celldex was forced into the aggressive reverse split after the stock crashed 84 percent in the past year as the market lost its optimism about immunotherapy combination treatments.
HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about. One you should ...
Celldex Therapeutics, Inc. (CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Beginning on February 11, 2019, Celldex’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the new CUSIP number 15117B202. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on June 13, 2018, Celldex stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a ratio of not less than one-for-ten and not more than one-for-fifteen.
CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Moleculin Biotech Inc (MBRX), Celldex Therapeutics Inc (CLDX), and Teladoc Health Inc (TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...